Hepatitis C virus recurrence and immunosuppression-free state after liver transplantation

Expert Review of Clinical Immunology

Volumn 8, Issue 7, 2012, Pages 635-644

  Manzia, Tommaso Maria ^a   Angelico, Roberta ^a   Toti, Luca ^a   Lai, Quirino ^b   Ciano, Paolo ^a   Angelico, Mario ^a   Tisone, Giuseppe ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

clinical operational tolerance; HCV recurrence; hepatitis C; immunosuppression; liver transplantation

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PEGINTERFERON; RIBAVIRIN; IMMUNOSUPPRESSIVE AGENT;

ANTIVIRAL THERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENCY; GRAFT SURVIVAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; NONHUMAN; RECURRENT INFECTION; REVIEW; TRANSPLANTATION TOLERANCE; TREATMENT RESPONSE; VIRUS REPLICATION; FEMALE; IMMUNOLOGY; RECURRENT DISEASE;

FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; RECURRENCE;

EID: 84867751995     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.12.66     Document Type: Review

References (66)

1. Berenguer M, López-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J. Hepatol. 35(5), 666-678 (2001).
2. Watt K, Veldt B, Charlton M. A practical guide to the management of HCV infection following liver transplantation. Am. J. Transplant. 9(8), 1707-1713 (2009).
3. Gonzalez SA. Management of recurrent hepatitis C following liver transplantation. Gastroenterol. Hepatol. (N. Y). 6(10), 637-645 (2010).
4. Roche B, Samuel D. Hepatitis C virus treatment pre- and post-liver transplantation. Liver Int. 32(Suppl. 1), 120-128 (2012).
5. Samonakis DN, Germani G, Burroughs AK. Immunosuppression and HCV recurrence after liver transplantation. J. Hepatol. 56(4), 973-983 (2012).
6. Trotter JF. Hot-topic debate on hepatitis C virus: The type of immunosuppression matters. Liver Transpl. 17(Suppl. 3), S20-S23 (2011).
7. Lake Jr. The role of immunosuppression in recurrence of hepatitis C. Liver Transpl. 9(11), S63-S66 (2003). (Pubitemid 37408006)
8. Orlando G, Soker S, Wood K. Operational tolerance after liver transplantation. J. Hepatol. 50(6), 1247-1257 (2009).
9. Lerut J, Sanchez-Fueyo A. An appraisal of tolerance in liver transplantation. Am. J. Transplant. 6(8), 1774-1780 (2006). (Pubitemid 44024949)
10. McCaughan GW, Shackel NA, Bertolino P, Bowen DG. Molecular and cellular aspects of hepatitis C virus reinfection after liver transplantation: how the early phase impacts on outcomes. Transplantation 87(8), 1105-1111 (2009).
11. Berenguer M, Ferrell L, Watson J et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J. Hepatol. 32(4), 673-684 (2000). (Pubitemid 30180389)
12. Rubín A, Aguilera V, Berenguer M. Liver transplantation and hepatitis C. Clin. Res. Hepatol. Gastroenterol. 35(12), 805-812 (2011).
13. Graziadei IW, Zoller HM, Schloegl A et al. Early viral load and recipient interleukin-28B rs12979860 genotype are predictors of the progression of hepatitis C after liver transplantation. Liver Transpl. 18(6), 671-679 (2012).
14. Belli LS, Burra P, Poli F et al. HLA-DRB1 donor-recipient mismatch affects the outcome of hepatitis C disease recurrence after liver transplantation. Gastroenterology 130(3), 695-702 (2006). (Pubitemid 43374520)
15. Charlton MR, Thompson A, Veldt BJ et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 53(1), 317-324 (2011).
16. Fukuhara T, Taketomi A, Motomura T et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 139(5), 1577-85, 1585.e1 (2010).
17. Ducoulombier D, Roque-Afonso AM, Di Liberto G et al. Frequent compartmentalization of hepatitis C virus variants in circulating B cells and monocytes. Hepatology 39(3), 817-825 (2004). (Pubitemid 38337663)
18. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: A tale of coevolution and coexistence. J. Clin. Invest. 119(7), 1745-1754 (2009).
19. Chinnadurai R, Velazquez V, Grakoui A. Hepatic transplant and HCV: A new playground for an old virus. Am. J. Transplant. 12(2), 298-305 (2012).
20. Khakoo SI, Thio CL, Martin MP et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305(5685), 872-874 (2004). (Pubitemid 39038423)
21. Neumann UP, Berg T, Bahra M et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J. Hepatol. 41(5), 830-836 (2004). (Pubitemid 39434314)
22. Ramírez S, Pérez-Del-Pulgar S, Forns X. Virology and pathogenesis of hepatitis C virus recurrence. Liver Transpl. 14(Suppl. 2), S27-S35 (2008).
23. Rosen HR. Transplantation immunology: what the clinician needs to know for immunotherapy. Gastroenterology 134(6), 1789-1801 (2008). (Pubitemid 351626955)
24. Saito T, Gale M Jr. Regulation of innate immunity against hepatitis C virus infection. Hepatol. Res. 38(2), 115-122 (2008).
25. Rosen HR, Doherty DG, Madrigal-Estebas L, O'Farrelly C, Golden-Mason L. Pretransplantation CD56(+) innate lymphocyte populations associated with severity of hepatitis C virus recurrence. Liver Transpl. 14(1), 31-40 (2008). (Pubitemid 351167986)
26. Weston SJ, Leistikow RL, Reddy KR et al. Reconstitution of hepatitis C virus-specific T-cell mediated immunity after liver transplantation. Hepatology 41(1), 72-81 (2005). (Pubitemid 40068845)
27. Berenguer M, Aguilera V, Prieto M et al. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J. Hepatol. 44(4), 717-722 (2006).
28. Terrault NA, Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transpl. 12(8), 1192-1204 (2006). (Pubitemid 44194586)
29. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J. Hepatol. 49(2), 274-287 (2008).
30. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: A review and quantitative analysis. Am. J. Transplant. 6(7), 1586-1599 (2006). (Pubitemid 43945798)
31. Xirouchakis E, Triantos C, Manousou P et al. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. J. Viral Hepat. 15(10), 699-709 (2008).
32. Asselah T, Marcellin P. New direct-acting antivirals' combination for the treatment of chronic hepatitis C. Liver Int. 31(Suppl. 1), 68-77 (2011).
33. Berenguer M. Hot topic in hepatitis C virus research: The type of immunosuppression does not matter. Liver Transpl. 17(Suppl. 3), S24-S28 (2011).
34. Nakagawa M, Sakamoto N, Tanabe Y et al. Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology 129(3), 1031-1041 (2005). (Pubitemid 41242693)
35. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38(5), 1282-1288 (2003). (Pubitemid 37314838)
36. Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl. 13(1), 21-29 (2007). (Pubitemid 46099970)
37. Germani G, Pleguezuelo M, Villamil F et al. Azathioprine in liver transplantation: A reevaluation of its use and a comparison with mycophenolate mofetil. Am. J. Transplant. 9(8), 1725-1731 (2009).
38. Manzia TM, Angelico R, Toti L et al. Long-term, maintenance MMF monotherapy improves the fibrosis progression in liver transplant recipients with recurrent hepatitis C. Transpl. Int. 24(5), 461-468 (2011).
39. Bahra M, Neumann UI, Jacob D et al. MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course. Am. J. Transplant. 5(2), 406-411 (2005). (Pubitemid 40179529)
40. Veldt BJ, Poterucha JJ, Watt KD et al. Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am. J. Transplant. 9(6), 1406-1413 (2009).
41. Foxton MR, Quaglia A, Muiesan P et al. The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am. J. Transplant. 6(8), 1922-1929 (2006). (Pubitemid 44024965)
42. Orlando G, Hematti P, Stratta RJ et al. Clinical operational tolerance after renal transplantation: current status and future challenges. Ann. Surg. 252(6), 915-928 (2010).
43. Karam VH, Gasquet I, Delvart V et al. Quality of life in adult survivors beyond 10 years after liver, kidney, and heart transplantation. Transplantation 76(12), 1699-1704 (2003). (Pubitemid 38032417)
44. Josh L. Operational tolerance: Past lessons and future prospects. Liver transpl. 17, 222-232 (2011).
45. Sánchez-Fueyo A. Identification of tolerant recipients following liver transplantation. Int. Immunopharmacol. 10(12), 1501-1504 (2010).
46. Sánchez-Fueyo A. Hot-topic debate on tolerance: immunosuppression withdrawal. Liver Transpl. 17(Suppl. 3), S69-S73 (2011).
47. Orlando G. Finding the right time for weaning off immunosuppression in solid organ transplant recipients. Expert Rev. Clin. Immunol. 6(6), 879-892 (2010).
48. Starzl TE, Demetris AJ, Trucco M et al. Cell migration and chimerism after whole-organ transplantation: The basis of graft acceptance. Hepatology 17(6), 1127-1152 (1993). (Pubitemid 23187422)
49. Reyes J, Zeevi A, Ramos H et al. Frequent achievement of a drug-free state after orthotopic liver transplantation. Transplant. Proc. 25(6), 3315-3319 (1993). (Pubitemid 24007333)
50. Ramos HC, Reyes J, Abu-Elmagd K et al. Weaning of immunosuppression in long-term liver transplant recipients. Transplantation 59(2), 212-217 (1995).
51. Tzakis AG, Reyes J, Zeevi A et al. Early tolerance in pediatric liver allograft recipients. J. Pediatr. Surg. 29(6), 754-756 (1994). (Pubitemid 24191356)
52. Mazariegos GV, Reyes J, Marino IR et al. Weaning of immunosuppression in liver transplant recipients. Transplantation 63(2), 243-249 (1997). (Pubitemid 27121206)
53. Mazariegos GV, Sindhi R, Thomson AW, Marcos A. Clinical tolerance following liver transplantation: long term results and future prospects. Transpl. Immunol. 17(2), 114-119 (2007). (Pubitemid 46240885)
54. Devlin J, Doherty D, Thomson L et al. Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology 27(4), 926-933 (1998). (Pubitemid 28160476)
55. Girlanda R, Rela M, Williams R, O'Grady JG, Heaton ND. Long-term outcome of immunosuppression withdrawal after liver transplantation. Transplant. Proc. 37(4), 1708-1709 (2005). (Pubitemid 40790804)
56. Andreoni KA, Lin JI, Groben PA. Liver transplantation 27 years after bone marrow transplantation from the same living donor. N. Engl. J. Med. 350(25), 2624-2625 (2004). (Pubitemid 38758556)
57. Eason JD, Cohen AJ, Nair S, Alcantera T, Loss GE. Tolerance: is it worth the risk? Transplantation 79(9), 1157-1159 (2005). (Pubitemid 40664015)
58. Tryphonopoulos P, Tzakis AG, Weppler D et al. The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation. Am. J. Transplant. 5(3), 608-613 (2005). (Pubitemid 40313354)
59. Tryphonopoulos P, Ruiz P, Weppler D et al. Long-term follow-up of 23 operational tolerant liver transplant recipients. Transplantation 90(12), 1556-1561 (2010).
60. Tisone G, Orlando G, Cardillo A et al. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J. Hepatol. 44(4), 702-709 (2006).
61. Orlando G, Manzia T, Baiocchi L, Sanchez-Fueyo A, Angelico M, Tisone G. The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients: The updated follow up at 78 months. Transpl. Immunol. 20(1-2), 43-47 (2008).
62. Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J. Hepatol. 22(6), 696-699 (1995).
63. Manzia TM, Cillis A, Angelico R et al. Ten years of weaning-off immunosuppression in stable HCV liver transplant recipients. Presented at: American Transplant Congress. Philadelphia, PA, USA, 30 April-4 May 2011.
64. Martínez-Llordella M, Puig-Pey I, Orlando G et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am. J. Transplant. 7(2), 309-319 (2007). (Pubitemid 46096324)
65. Martínez-Llordella M, Lozano JJ, Puig-Pey I et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J. Clin. Invest. 118(8), 2845-2857 (2008).
66. Bohne F, Martínez-Llordella M, Lozano JJ et al. Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. J. Clin. Invest. 122(1), 368-382 (2012).